ClinicalTrials.gg
CompletedNCT04397263Updated Oct 7, 2026Results posted

A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

A Phase 3 interventional study of Guselkumab in Crohns Disease, sponsored by Janssen Pharmaceutical K.K.. Completed at 25 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Janssen Pharmaceutical K.K. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Updated Oct 7, 2026Study documents postedPosted results revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
38
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing guselkumab in Crohn Disease — 6 open to participants now, 11 under way, 7 of them phase 3. guselkumab · Crohn Disease.

Enrollment
11th of 13
38 · median 196
Started
2020
the only one that year
Phase 3
8 of 13
3 open now
Registered
2nd of 13
by date
Lead sponsor
1 of 13
Janssen Pharmaceutical K.K.

Among the 13 studies testing guselkumab in Crohn Disease, this one is the 11th largest by enrollment, is the only one that started in 2020, is one of 8 in phase 3, and was the 2nd registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

6 of the 13 studies testing guselkumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About guselkumab

guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing guselkumab in Crohn Disease, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety of Guselkumab in participants with Crohn's disease.

03

Conditions studied

  • Crohns Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have Crohn's Disease (CD) or fistulizing CD of at least 3 months duration (defined as a minimum of 12 weeks), with colitis, ileitis, or ileocolitis, confirmed at any time in the past by radiography, histology, and/or endoscopy
  • Have moderate to severe CD as assessed by CDAI components of stool frequency (SF), and abdominal pain (AP) scores, and endoscopic evidence
  • Have screening laboratory test results within the protocol specified parameters
  • A female participant of must have a negative urine pregnancy test result at screening and baseline
  • Demonstrated intolerance or inadequate response to conventional or to biologic therapy for CD

Exclusion criteria

Exclusion Criteria:

  • Has complications of CD, such as symptomatic strictures or stenoses, short gut syndrome, or any other manifestation
  • Unstable doses of concomitant Crohn's disease therapy
  • Receipt of Crohn's disease approved biologic agents, agents, or procedures outside of permitted time frame as specified in the protocol
  • Prior exposure to p40 inhibitors or p19 inhibitors
  • Any medical preventing study participation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Guselkumab

    Participants will receive guselkumab by intravenous (IV) infusion, followed by guselkumab by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the Long-term extension (LTE) phase and continue to receive guselkumab.

    Drug: Guselkumab

Interventions

  • Guselkumab will be administered intravenously for the first 3 doses and then subcutaneously for the subsequent doses.

    Also known as: CNTO1959

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Number of participants with TEAEs were reported. An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Treatment-emergent AEs (TEAEs) were AEs with onset during the intervention phase or that were a consequence of a pre-existing condition that had worsened since baseline. All TEAEs including serious and non-serious AEs were reported.

    Time frame: From baseline (Week 0) up to Week 48

  2. Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)

    Number of participants with TESAEs were reported. TEAEs are AEs with onset during the intervention phase or that are a consequence of a pre-existing condition that had worsened since baseline. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: From baseline (Week 0) up to Week 48

  3. Number of Participants With Treatment-emergent Adverse Events of Special Interest (TEAESI)

    Number of participants with TEAESI was reported. Active tuberculosis (TB) or malignancies were considered as TEAESIs. TEAESIs were AESIs with onset during the intervention phase or that are a consequence of a pre-existing condition that had worsened since baseline.

    Time frame: From baseline (Week 0) up to Week 48

  4. Number of Participants With Treatment-emergent Abnormalities in Hematology Laboratory Parameters

    Number of participants with treatment-emergent abnormalities in hematology laboratory parameters were reported. Laboratory tests included in hematology were hemoglobin, lymphocytes, neutrophils, platelet count, Total WBC (white blood cell) Count. National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) toxicity grades were Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe), Grade 4 (Potentially Life-Threatening). TE abnormalities are laboratory abnormalities with onset during the intervention phase or that are a consequence of a pre-existing condition that had worsened since baseline.

    Time frame: From baseline (Week 0) up to Week 48

  5. Number of Participants With Treatment-emergent Abnormalities in Chemistry Laboratory Parameters

    Number of participants with treatment-emergent abnormalities in chemistry laboratory parameters were reported. Laboratory parameters included in clinical chemistry were albumin, corrected calcium, creatinine, glucose, potassium, sodium. NCI-CTCAE) toxicity grades were Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe), Grade 4 (Potentially Life-Threatening). TE abnormalities are laboratory abnormalities with onset during the intervention phase or that are a consequence of a pre-existing condition that had worsened since baseline.

    Time frame: From baseline (Week 0) up to Week 48

  6. Number of Participants With TEAEs of Infections

    Number of participants with TEAEs of infections were reported. TEAEs are AEs with onset during the intervention phase or that are a consequence of a pre-existing condition that had worsened since baseline.

    Time frame: From baseline (Week 0) up to Week 48

  7. Number of Participants With TEAEs of Injection-site Reactions

    Number of participants with TEAEs of injection-site reactions were reported. A significant injection-site reaction was defined as an adverse reaction that was manifested through 1 or more of the following symptoms: significant bruising, erythema, hemorrhage, irritation, pain, pruritus at the site of injection. TEAEs are AEs with onset during the intervention phase or that are a consequence of a pre-existing condition that has worsened since baseline.

    Time frame: From baseline (Week 0) up to Week 48

  8. Number of Participants With TEAEs Temporally Associated With Infusion

    Number of participants with TEAEs temporally associated with infusion were reported. TEAEs are AEs with onset during the intervention phase or that are a consequence of a preexisting condition that had worsened since baseline.

    Time frame: From baseline (Week 0) up to Week 48

  9. Number of Participants With TEAEs of Suicidal Ideation, Suicidal Behavior, or Self-Injurious Behavior Without Suicidal Intent

    TEAEs are AEs with onset during the intervention phase or that are a consequence of a pre-existing condition that had worsened since baseline. The Columbia-suicide severity rating scale (C-SSRS) defined was 5 subtypes of suicidal ideation and 4 possible suicidal behaviors, as well as non-suicidal self-injurious behavior and completed suicide. The C-SSRS was an investigator-administered questionnaire: 1) No suicidal ideation or behaviors (including self-injurious behavior without suicidal intent): No further action was needed; 2) Suicidal ideation levels 1-3 or non-suicidal self-injurious behavior; participant risk is assessed by the investigator. 3) Suicidal ideation levels 4 or 5 or any suicidal behavior: participant risk assessed and referral to a mental health professional. If no events qualify for scores of 1 to 10, score of 0 was assigned (0= "no event that can be assessed on the basis of C-SSRS"). Higher scores indicated greater severity.

    Time frame: From baseline (Week 0) up to Week 48

  10. Number of Participants With Clinically Significant Treatment-emergent Abnormalities in Vital Signs

    Number of participants with clinically significant treatment-emergent abnormalities in vital signs were reported. Vital signs included weight, pulse rate, temperature, respiratory rate, systolic blood pressure, and diastolic blood pressure. TEAEs are AEs with onset during the intervention phase or that are a consequence of a pre-existing condition that had worsened since baseline.

    Time frame: From baseline (Week 0) up to Week 48

  11. Number of Participants With Concomitant Medications for Crohn's Disease

    Number of participants with concomitant medications for Crohn's disease were reported.

    Time frame: From screening (Week -8) up to Week 48

Secondary outcomes

  1. Number of Participants With Clinical Response Through Week 48

    Number of participants with clinical response through Week 48 were reported. Clinical response was defined as a greater than or equal to (\>=) 100-point reduction from baseline in CDAI score or CDAI score less than (\<) 150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.

    Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48

  2. Number of Participants With Clinical Remission Through Week 48

    Number of participants with clinical remission through Week 48 were reported. Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.

    Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48

  3. Number of Participants With Patient-reported Outcome(s) (PRO)-2 Remission Through Week 48

    Number of participants with PRO-2 remission through Week 48 were reported. PRO-2 remission was defined as abdominal pain (AP) mean daily score at or below 1 and stool frequency (SF) mean daily score at or below 3, and no worsening of AP or SF from baseline. Mean daily AP score was defined as the sum of abdominal pain/cramps ratings in the previous 7 days in a diary card divided by the total number of days assessments were performed. Average daily SF score was defined as the sum of number of liquid or very soft stools in the previous 7 days in a diary card divided by the total number of days assessments were performed. Mean daily SF and AP scores score at a scheduled visit were not calculated if total number of days of assessment was less than 5. Higher PRO-2 scores indicated more severe disease.

    Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48

  4. Change From Baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) Score at Week 48

    Change from baseline in SES-CD score at Week 48 were reported. The SES-CD score was used to evaluate endoscopic improvement. The SES-CD was based on the evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. Each endoscopic component was scored from 0 (best) to 3 (worst) for each segment, resulting in a total score of up to 15 for each component, except for the narrowing component which only attain a maximum total score of 11 because, the presence of a narrowing that cannot be passed can be only observed once. The total SES-CD score was the sum of all the component scores across all the segments and it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.

    Time frame: Baseline (Week 0) and Week 48

  5. Serum Concentation of Guselkumab

    Serum concentration of guselkumab were reported.

    Time frame: Predose at Weeks 0, 4, 8, 12, 16, 20, 24, 32, 40, 48 and 1 hour post dose at Weeks 0, 4, 8

  6. Number of Participants With Anti-Guselkumab Antibodies Through Week 48

    Number of participants with anti-guselkumab antibodies through Week 48 were reported.

    Time frame: From Week 0 through Week 48

  7. Number of Participants With Neutralizing-Guselkumab Antibodies Through Week 48

    Number of participants with neutralizing-guselkumab antibodies through Week 48 were reported.

    Time frame: From Week 0 through Week 48

  8. Change From Baseline in Inflammatory Pharmacodynamic (PD) Marker: C-reactive Protein (CRP) Concentration

    Change from baseline in inflammatory PD marker of CRP concentration were reported.

    Time frame: Baseline (Week 0), Weeks 4, 8, 12, 16, 20, 24, 32, 40 and 48

  9. Change From Baseline in Inflammatory PD Marker: Fecal Calprotectin (FC) Levels

    Change from baseline in inflammatory PD marker of FC levels were reported.

    Time frame: Baseline (Week 0), Weeks 4, 8, 12, 24, and 48

  10. Change From Baseline in Crohn's Disease Activity Index (CDAI) Score at Week 48 by Serum Guselkumab Concentration Quartiles at Week 48

    Change from baseline in CDAI score at Week 48 by serum guselkumab concentration quartiles at Week 48 were reported. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.

    Time frame: At Week 48

  11. Number of Participants in Clinical Response at Week 48 by Serum Guselkumab Concentration Quartiles at Week 48

    Number of participants in clinical response at Week 48 by serum guselkumab concentration quartiles at Week 48 were reported. Clinical response was defined as a \>=100-point reduction from baseline in CDAI score or CDAI score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.

    Time frame: At Week 48

  12. Number of Participants in Clinical Remission at Week 48 by Serum Guselkumab Concentration Quartiles at Week 48

    Number of participants in clinical remission at Week 48 by serum guselkumab concentration quartiles at Week 48 were reported. Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.

    Time frame: At Week 48

  13. Number of Participants in Endoscopic Response at Week 48 by Serum Guselkumab Concentration Quartiles at Week 48

    Number of participants in endoscopic response at Week 48 by serum guselkumab concentration quartiles at Week 48 were reported. Endoscopic response was defined as \>=50 % improvement from baseline in SES-CD score or SES-CD score less than or equal to (\<=) 2. The SES-CD was based on evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. Each endoscopic component was scored from 0 (best) to 3 (worst) for each segment, resulting in a total score of up to 15 for each component, except for narrowing component which only attain a maximum total score of 11 because, presence of a narrowing that cannot be passed can be only observed once. The total SES-CD score was sum of all component scores across all segments and it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.

    Time frame: At Week 48

  14. Number of Participants in Endoscopic Remission at Week 48 by Serum Guselkumab Concentration Quartiles at Week 48

    Number of participants in endoscopic remission at Week 48 by serum guselkumab concentration quartiles at Week 48 were reported. Endoscopic remission: an SES-CD score \<= 4 with at least a 2-point reduction from baseline and no sub score \>1 in any individual subcomponent. The SES-CD was based on evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. Each endoscopic component was scored from 0 (best) to 3 (worst) for each segment, resulting in total score of 15 for each component, except for narrowing component which only attain a maximum total score of 11 because, presence of a narrowing that cannot be passed can be only observed once. The total SES-CD score was sum of all component scores (all segments) \& it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.

    Time frame: At Week 48

  15. Change From Baseline in the Average Daily Prednisone-equivalent (P.Eq) Oral Corticosteroid Dose (Excluding Budesonide) Through Week 48 Among Participants Receiving Oral Corticosteroids Other Than Budesonide at Baseline

    Change from baseline in the average daily P.Eq oral corticosteroid dose (excluding Budesonide) through Week 48 among participants receiving oral corticosteroids other than Budesonide at baseline were reported.

    Time frame: Baseline (Week 0), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48

  16. Number of Participants Not Receiving Concomitant Corticosteroids at Week 48 Among Participants Receiving Concomitant Corticosteroids at Baseline

    Number of participants not receiving concomitant corticosteroids at Week 48 among participants receiving concomitant corticosteroids at baseline were reported.

    Time frame: At Week 48

  17. Number of Participants Not Receiving Concomitant Corticosteroids for at Least 30 Days Prior to Week 48 Among Participants Receiving Concomitant Corticosteroids at Baseline

    Number of participants not receiving concomitant corticosteroids for at least 30 days prior to Week 48 among participants receiving concomitant corticosteroids at baseline were reported.

    Time frame: Up to Week 48

  18. Number of Participants Not Receiving Concomitant Corticosteroids for at Least 90 Days Prior to Week 48 Among Participants Receiving Concomitant Corticosteroids at Baseline

    Number of participants not receiving concomitant corticosteroids for at least 90 days prior to Week 48 among participants receiving concomitant corticosteroids at baseline were reported.

    Time frame: Up to Week 48

  19. Number of Participants With Clinical Response Through LTE Phase

    Number of participants with clinical response through LTE phase were reported. Clinical response was defined as a \>=100-point reduction from baseline in CDAI score or CDAI score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.

    Time frame: Weeks 96, 144, 192, and 240

  20. Number of Participants With Clinical-biomarker Response Through LTE Phase

    Number of participants with clinical-biomarker response through LTE phase were reported. Clinical-biomarker response was defined as clinical response based on CDAI score and \>=50% reduction from baseline in CRP or FC. Clinical response: a \>=100-point reduction from baseline in CDAI score or CDAI score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug\[s\] and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.

    Time frame: Weeks 96, 144, 192, and 240

  21. Number of Participants With Clinical Remission Through LTE Phase

    Number of participants with clinical remission through LTE phase were reported. Clinical remission was defined as a CDAI score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.

    Time frame: Weeks 96, 144, 192, and 240

  22. Number of Participants With Endoscopic Response Through LTE Phase

    Number of participants in endoscopic response through LTE phase were reported. Endoscopic response was defined as \>=50 % improvement from baseline in SES-CD score or SES-CD score \<=2. The SES-CD was based on evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. Each endoscopic component was scored from 0 (best) to 3 (worst) for each segment, resulting in a total score of up to 15 for each component, except for narrowing component which only attain a maximum total score of 11 because, presence of a narrowing that cannot be passed can be only observed once. The total SES-CD score was sum of all component scores across all segments and it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.

    Time frame: Weeks 96, 144, 192, and 240

  23. Number of Participants With Endoscopic Remission Through LTE Phase

    Number of participants in endoscopic remission through LTE phase were reported. Endoscopic remission was defined as an SES-CD score \<= 4 with at least a 2-point reduction from baseline and no sub score \>1 in any individual subcomponent. The SES-CD was based on evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. Each endoscopic component was scored from 0 (best) to 3 (worst) for each segment, resulting in total score of 15 for each component, except for narrowing omponent which only attain a maximum total score of 11 because, presence of a narrowing that cannot be passed can be only observed once. The total SES-CD score was sum of all component scores (all segments) \& it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.

    Time frame: Weeks 96, 144, 192, and 240

  24. Number of Participants With Endoscopic Healing Through LTE Phase

    Number of participants With endoscopic healing through LTE phase were reported. Endoscopic healing was defined as the absence of mucosal ulcerations.

    Time frame: Weeks 96, 144, 192, and 240

  25. Change From Baseline in SES-CD Score During LTE Phase

    Change from baseline in SES-CD score during LTE phase were reported. The SES-CD was based on evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. Each endoscopic component was scored from 0 (best) to 3 (worst) for each segment, resulting in a total score of up to 15 for each component, except for narrowing component which only attain a maximum total score of 11 because, presence of a narrowing that cannot be passed can be only observed once. The total SES-CD score was sum of all component scores across all segments and it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.

    Time frame: Baseline (Week 0), 96, 144, 192, and 240

  26. Number of Participants With Patient-reported Outcome(s) (PRO)-2 Remission During LTE Phase

    Number of participants with PRO-2 remission during LTE phase were reported. PRO-2 remission was defined as abdominal pain (AP) mean daily score at or below 1 and stool frequency (SF) mean daily score at or below 3, and no worsening of AP or SF from baseline. Mean daily AP score was defined as the sum of abdominal pain/cramps ratings in the previous 7 days in a diary card divided by the total number of days assessments were performed. Average daily SF score was defined as the sum of number of liquid or very soft stools in the previous 7 days in a diary card divided by the total number of days assessments were performed. Mean daily SF and AP scores score at a scheduled visit were not calculated if total number of days of assessment was less than 5. Higher PRO-2 scores indicated more severe disease.

    Time frame: Weeks 96, 144, 192, and 240

  27. Number of Participants With Any Crohn's Disease-related Hospitalizations and/or Surgeries During the Study

    Number of participants with any Crohn's Disease-related hospitalizations and/or surgeries during the study were reported.

    Time frame: From Week 0 up to final efficacy visit for each participant (up to Week 248)

  28. Serum Guselkumab Concentrations During LTE Phase

    Serum guselkumab concentrations during LTE phase were reported.

    Time frame: Predose at Weeks 96, 144, 192, and 240

  29. Number of Participants With Anti-Guselkumab Antibodies During the Study

    Number of participants with anti-guselkumab antibodies during the study were reported.

    Time frame: From Week 0 up to the final immunogenicity visit for each participant (up to Week 248)

  30. Number of Participants With Neutralizing Antibodies to Guselkumab During the Study

    Number of participants with neutralizing-guselkumab antibodies during the study were reported.

    Time frame: From Week 0 up to the final immunogenicity visit for each participant (up to Week 248)

  31. Change From Baseline in Inflammatory Pharmacodynamic (PD) Marker: C-reactive Protein (CRP) Concentration During LTE Phase

    Change from baseline in inflammatory PD marker of CRP concentration during LTE phase were reported.

    Time frame: Baseline (Week 0), Weeks 64, 80, 96, 112, 128, 144, 160, 176, 192, 208, 224, and 240

  32. Change From Baseline in Inflammatory PD Marker: FC Levels Concentration During LTE Phase

    Change from baseline in inflammatory PD marker of FC levels during LTE phase were reported.

    Time frame: Baseline (Week 0), Weeks 64, 80, 96, 112, 128, 144, 160, 176, 192, 208, 224, and 240

  33. Change From Baseline in CDAI Score at Week 96 by Serum Guselkumab Concentration Quartiles at Week 96

    Change from baseline in CDAI score at Week 96 by serum guselkumab concentration quartiles at Week 96 were reported. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.

    Time frame: Baseline (Week 0) and Week 96

  34. Number of Participants in Clinical Response at Week 96 by Serum Guselkumab Concentration Quartiles at Week 96

    Number of participants in clinical response at Week 96 by serum guselkumab concentration quartiles at Week 96 were reported. Clinical response was defined as a \>=100-point reduction from baseline in CDAI score or CDAI score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.

    Time frame: At Week 96

  35. Number of Participants in Clinical Remission at Week 96 by Serum Guselkumab Concentration Quartiles at Week 96

    Number of participants in clinical remission at Week 96 by serum guselkumab concentration quartiles at Week 96 were reported. Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.

    Time frame: At Week 96

  36. Number of Participants in Endoscopic Response at Week 96 by Serum Guselkumab Concentration Quartiles at Week 96

    Number of participants in endoscopic response at Week 96 by serum guselkumab concentration quartiles at Week 96 were reported. Endoscopic response was defined as \>=50 % improvement from baseline in SES-CD score or SESCD score less than or equal to (\<=) 2. The SES-CD was based on evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. Each endoscopic component was scored from 0 (best) to 3 (worst) for each segment, resulting in a total score of up to 15 for each component, except for narrowing component which only attain a maximum total score of 11 because, presence of a narrowing that cannot be passed can be only observed once. The total SES-CD score was sum of all component scores across all segments and it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.

    Time frame: At Week 96

  37. Number of Participants in Endoscopic Remission at Week 96 by Serum Guselkumab Concentration Quartiles at Week 96

    Number of participants in endoscopic remission at Week 96 by serum guselkumab concentration quartiles at Week 96 were reported. Endoscopic remission: an SES-CD score \<= 4 with at least a 2-point reduction from baseline and no sub score \>1 in any individual subcomponent. The SES-CD was based on evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. Each endoscopic component was scored from 0 (best) to 3 (worst) for each segment, resulting in total score of 15 for each component, except for narrowing component which only attain a maximum total score of 11 because, presence of a narrowing that cannot be passed can be only observed once. The total SES-CD score was sum of all component scores (all segments) \& it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.

    Time frame: At Week 96

  38. Change From Baseline in the Average Daily Prednisone-equivalent (P.Eq) Oral Corticosteroid Dose (Excluding Budesonide) During LTE Phase Among Participants Receiving Oral Corticosteroids Other Than Budesonide at Baseline

    Change from baseline in the average daily P.Eq oral corticosteroid dose (excluding Budesonide) during LTE phase among participants receiving oral corticosteroids other than Budesonide at baseline were reported.

    Time frame: Baseline (Week 0), Weeks 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, 112, 116, 120, 124, 128, 132, 136, 140, 144, 148, 152, 156, 160, 164, 168, 172, 176, 180, 184, 188, 192, 196, 200, 204, 208, 212, 216, 220, 224, 228, and 232

07

Results

Posted May 20, 2025

Participant flow

Open-label Phase: Week 0 Till Week 48
Participant flow — Open-label Phase: Week 0 Till Week 48
MilestoneGuselkumab 200 Milligrams (mg)
Started38
Completed36
Not completed2
Withdrew: Withdrawal by subject2
LTE Phase: Week 48 Till Week 248
Participant flow — LTE Phase: Week 48 Till Week 248
MilestoneGuselkumab 200 Milligrams (mg)
Started33
Lte safety analysis set32
Completed28
Not completed5
Withdrew: Adverse event2
Withdrew: Lack of efficacy1
Withdrew: Withdrawal by subject1
Withdrew: Cd related surgery1

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

Number of participants with TEAEs were reported. An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Treatment-emergent AEs (TEAEs) were AEs with onset during the intervention phase or that were a consequence of a pre-existing condition that had worsened since baseline. All TEAEs including serious and non-serious AEs were reported.

Time frame:
From baseline (Week 0) up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsGuselkumab 200 Milligrams (mg)
Number of Participants With Treatment-emergent Adverse Events (TEAEs)33
PrimaryNumber of Participants With Treatment-emergent Serious Adverse Events (TESAEs)

Number of participants with TESAEs were reported. TEAEs are AEs with onset during the intervention phase or that are a consequence of a pre-existing condition that had worsened since baseline. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame:
From baseline (Week 0) up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
ParticipantsGuselkumab 200 Milligrams (mg)
Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)3
PrimaryNumber of Participants With Treatment-emergent Adverse Events of Special Interest (TEAESI)

Number of participants with TEAESI was reported. Active tuberculosis (TB) or malignancies were considered as TEAESIs. TEAESIs were AESIs with onset during the intervention phase or that are a consequence of a pre-existing condition that had worsened since baseline.

Time frame:
From baseline (Week 0) up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events of Special Interest (TEAESI)
ParticipantsGuselkumab 200 Milligrams (mg)
Number of Participants With Treatment-emergent Adverse Events of Special Interest (TEAESI)0
PrimaryNumber of Participants With Treatment-emergent Abnormalities in Hematology Laboratory Parameters

Number of participants with treatment-emergent abnormalities in hematology laboratory parameters were reported. Laboratory tests included in hematology were hemoglobin, lymphocytes, neutrophils, platelet count, Total WBC (white blood cell) Count. National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) toxicity grades were Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe), Grade 4 (Potentially Life-Threatening). TE abnormalities are laboratory abnormalities with onset during the intervention phase or that are a consequence of a pre-existing condition that had worsened since baseline.

Time frame:
From baseline (Week 0) up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Abnormalities in Hematology Laboratory Parameters
ParticipantsGuselkumab 200 Milligrams (mg)
Hemoglobin (increased): Grade 10
Hemoglobin (increased): Grade 20
Hemoglobin (increased): Grade 30
Hemoglobin (increased): Grade 40
Hemoglobin (decreased): Grade 118
Hemoglobin (decreased): Grade 22
Hemoglobin (decreased): Grade 33
Hemoglobin (decreased): Grade 40
Lymphocytes (increased): Grade 10
Lymphocytes (increased): Grade 20
Lymphocytes (increased): Grade 30
Lymphocytes (increased): Grade 40
Lymphocytes (decreased): Grade 15
Lymphocytes (decreased): Grade 27
Lymphocytes (decreased): Grade 34
Lymphocytes (decreased): Grade 40
Neutrophils (decreased): Grade 17
Neutrophils (decreased): Grade 27
Neutrophils (decreased): Grade 30
Neutrophils (decreased): Grade 40
Platelets (decreased): Grade 11
Platelets (decreased): Grade 20
Platelets (decreased): Grade 30
Platelets (decreased): Grade 40
Total WBC Count (increased): Grade 10
Total WBC Count (increased): Grade 20
Total WBC Count (increased): Grade 30
Total WBC Count (increased): Grade 40
Total WBC Count (decreased): Grade 19
Total WBC Count (decreased): Grade 29
Total WBC Count (decreased): Grade 30
Total WBC Count (decreased): Grade 40
PrimaryNumber of Participants With Treatment-emergent Abnormalities in Chemistry Laboratory Parameters

Number of participants with treatment-emergent abnormalities in chemistry laboratory parameters were reported. Laboratory parameters included in clinical chemistry were albumin, corrected calcium, creatinine, glucose, potassium, sodium. NCI-CTCAE) toxicity grades were Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe), Grade 4 (Potentially Life-Threatening). TE abnormalities are laboratory abnormalities with onset during the intervention phase or that are a consequence of a pre-existing condition that had worsened since baseline.

Time frame:
From baseline (Week 0) up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Abnormalities in Chemistry Laboratory Parameters
ParticipantsGuselkumab 200 Milligrams (mg)
Albumin (decreased): Grade 10
Albumin (decreased): Grade 21
Albumin (decreased): Grade 30
Albumin (decreased): Grade 40
Corrected Calcium (increased): Grade 10
Corrected Calcium (increased): Grade 20
Corrected Calcium (increased): Grade 30
Corrected Calcium (increased): Grade 40
Corrected Calcium (decreased): Grade 13
Corrected Calcium (decreased): Grade 20
Corrected Calcium (decreased): Grade 30
Corrected Calcium (decreased): Grade 40
Creatinine (increased): Grade 12
Creatinine (increased): Grade 21
Creatinine (increased): Grade 30
Creatinine (increased): Grade 40
Glucose (decreased): Grade 11
Glucose (decreased): Grade 21
Glucose (decreased): Grade 30
Glucose (decreased): Grade 40
Potassium (increased): Grade 10
Potassium (increased): Grade 21
Potassium (increased): Grade 30
Potassium (increased): Grade 40
Potassium (decreased): Grade 10
Potassium (decreased): Grade 25
Potassium (decreased): Grade 30
Potassium (decreased): Grade 40
Sodium (increased): Grade 10
Sodium (increased): Grade 20
Sodium (increased): Grade 30
Sodium (increased): Grade 40
Sodium (decreased): Grade 10
Sodium (decreased): Grade 20
Sodium (decreased): Grade 30
Sodium (decreased): Grade 40
PrimaryNumber of Participants With TEAEs of Infections

Number of participants with TEAEs of infections were reported. TEAEs are AEs with onset during the intervention phase or that are a consequence of a pre-existing condition that had worsened since baseline.

Time frame:
From baseline (Week 0) up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With TEAEs of Infections
ParticipantsGuselkumab 200 Milligrams (mg)
Number of Participants With TEAEs of Infections11
PrimaryNumber of Participants With TEAEs of Injection-site Reactions

Number of participants with TEAEs of injection-site reactions were reported. A significant injection-site reaction was defined as an adverse reaction that was manifested through 1 or more of the following symptoms: significant bruising, erythema, hemorrhage, irritation, pain, pruritus at the site of injection. TEAEs are AEs with onset during the intervention phase or that are a consequence of a pre-existing condition that has worsened since baseline.

Time frame:
From baseline (Week 0) up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With TEAEs of Injection-site Reactions
ParticipantsGuselkumab 200 Milligrams (mg)
Number of Participants With TEAEs of Injection-site Reactions3
PrimaryNumber of Participants With TEAEs Temporally Associated With Infusion

Number of participants with TEAEs temporally associated with infusion were reported. TEAEs are AEs with onset during the intervention phase or that are a consequence of a preexisting condition that had worsened since baseline.

Time frame:
From baseline (Week 0) up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With TEAEs Temporally Associated With Infusion
ParticipantsGuselkumab 200 Milligrams (mg)
Number of Participants With TEAEs Temporally Associated With Infusion0
PrimaryNumber of Participants With TEAEs of Suicidal Ideation, Suicidal Behavior, or Self-Injurious Behavior Without Suicidal Intent

TEAEs are AEs with onset during the intervention phase or that are a consequence of a pre-existing condition that had worsened since baseline. The Columbia-suicide severity rating scale (C-SSRS) defined was 5 subtypes of suicidal ideation and 4 possible suicidal behaviors, as well as non-suicidal self-injurious behavior and completed suicide. The C-SSRS was an investigator-administered questionnaire: 1) No suicidal ideation or behaviors (including self-injurious behavior without suicidal intent): No further action was needed; 2) Suicidal ideation levels 1-3 or non-suicidal self-injurious behavior; participant risk is assessed by the investigator. 3) Suicidal ideation levels 4 or 5 or any suicidal behavior: participant risk assessed and referral to a mental health professional. If no events qualify for scores of 1 to 10, score of 0 was assigned (0= "no event that can be assessed on the basis of C-SSRS"). Higher scores indicated greater severity.

Time frame:
From baseline (Week 0) up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With TEAEs of Suicidal Ideation, Suicidal Behavior, or Self-Injurious Behavior Without Suicidal Intent
ParticipantsGuselkumab 200 Milligrams (mg)
Number of Participants With TEAEs of Suicidal Ideation, Suicidal Behavior, or Self-Injurious Behavior Without Suicidal Intent0
PrimaryNumber of Participants With Clinically Significant Treatment-emergent Abnormalities in Vital Signs

Number of participants with clinically significant treatment-emergent abnormalities in vital signs were reported. Vital signs included weight, pulse rate, temperature, respiratory rate, systolic blood pressure, and diastolic blood pressure. TEAEs are AEs with onset during the intervention phase or that are a consequence of a pre-existing condition that had worsened since baseline.

Time frame:
From baseline (Week 0) up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Treatment-emergent Abnormalities in Vital Signs
ParticipantsGuselkumab 200 Milligrams (mg)
Number of Participants With Clinically Significant Treatment-emergent Abnormalities in Vital Signs0
PrimaryNumber of Participants With Concomitant Medications for Crohn's Disease

Number of participants with concomitant medications for Crohn's disease were reported.

Time frame:
From screening (Week -8) up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With Concomitant Medications for Crohn's Disease
ParticipantsGuselkumab 200 Milligrams (mg)
Oral amino salicylates28
6- mercaptopurine/azathioprine16
oral corticosteroids12
SecondaryNumber of Participants With Clinical Response Through Week 48

Number of participants with clinical response through Week 48 were reported. Clinical response was defined as a greater than or equal to (\>=) 100-point reduction from baseline in CDAI score or CDAI score less than (\<) 150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.

Time frame:
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48
Reported as:
Count of participants · Participants
Number of Participants With Clinical Response Through Week 48
ParticipantsGuselkumab 200 Milligrams (mg)
Week 420
Week 825
Week 1230
Week 1628
Week 2028
Week 2430
Week 2829
Week 3229
Week 3629
Week 4028
Week 4429
Week 4831
SecondaryNumber of Participants With Clinical Remission Through Week 48

Number of participants with clinical remission through Week 48 were reported. Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.

Time frame:
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48
Reported as:
Count of participants · Participants
Number of Participants With Clinical Remission Through Week 48
ParticipantsGuselkumab 200 Milligrams (mg)
Week 417
Week 819
Week 1223
Week 1623
Week 2022
Week 2425
Week 2825
Week 3225
Week 3626
Week 4023
Week 4425
Week 4829
SecondaryNumber of Participants With Patient-reported Outcome(s) (PRO)-2 Remission Through Week 48

Number of participants with PRO-2 remission through Week 48 were reported. PRO-2 remission was defined as abdominal pain (AP) mean daily score at or below 1 and stool frequency (SF) mean daily score at or below 3, and no worsening of AP or SF from baseline. Mean daily AP score was defined as the sum of abdominal pain/cramps ratings in the previous 7 days in a diary card divided by the total number of days assessments were performed. Average daily SF score was defined as the sum of number of liquid or very soft stools in the previous 7 days in a diary card divided by the total number of days assessments were performed. Mean daily SF and AP scores score at a scheduled visit were not calculated if total number of days of assessment was less than 5. Higher PRO-2 scores indicated more severe disease.

Time frame:
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48
Reported as:
Count of participants · Participants
Number of Participants With Patient-reported Outcome(s) (PRO)-2 Remission Through Week 48
ParticipantsGuselkumab 200 Milligrams (mg)
Week 46
Week 812
Week 1216
Week 1616
Week 2019
Week 2418
Week 2821
Week 3219
Week 3620
Week 4021
Week 4423
Week 4822
SecondaryChange From Baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) Score at Week 48

Change from baseline in SES-CD score at Week 48 were reported. The SES-CD score was used to evaluate endoscopic improvement. The SES-CD was based on the evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. Each endoscopic component was scored from 0 (best) to 3 (worst) for each segment, resulting in a total score of up to 15 for each component, except for the narrowing component which only attain a maximum total score of 11 because, the presence of a narrowing that cannot be passed can be only observed once. The total SES-CD score was the sum of all the component scores across all the segments and it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.

Time frame:
Baseline (Week 0) and Week 48
Reported as:
Mean · score on a scale
Change From Baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) Score at Week 48
score on a scaleGuselkumab 200 Milligrams (mg)
Change From Baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) Score at Week 48-6.4 ± 7.00
SecondarySerum Concentation of Guselkumab

Serum concentration of guselkumab were reported.

Time frame:
Predose at Weeks 0, 4, 8, 12, 16, 20, 24, 32, 40, 48 and 1 hour post dose at Weeks 0, 4, 8
Reported as:
Mean · micrograms/milliliter (mcg/mL)
Serum Concentation of Guselkumab
micrograms/milliliter (mcg/mL)Guselkumab 200 Milligrams (mg)
Week 0: pre-doseNA ± NA
Week 0: 1 hour post dose60.567 ± 7.8417
Week 4: pre-dose6.656 ± 2.5431
Week 4: 1 hour post dose63.556 ± 10.7183
Week 8: pre-dose8.679 ± 3.1697
Week 8: 1 hour post dose65.484 ± 7.8536
Week 12: pre-dose9.691 ± 4.4559
Week 16: pre-dose9.143 ± 4.3351
Week 20: pre-dose8.761 ± 4.3497
Week 24: pre-dose8.966 ± 4.6369
Week 32: pre-dose8.381 ± 3.7270
Week 40: pre-dose9.417 ± 5.3775
Week 48: pre-dose8.885 ± 4.4065
SecondaryNumber of Participants With Anti-Guselkumab Antibodies Through Week 48

Number of participants with anti-guselkumab antibodies through Week 48 were reported.

Time frame:
From Week 0 through Week 48
Reported as:
Count of participants · Participants
Number of Participants With Anti-Guselkumab Antibodies Through Week 48
ParticipantsGuselkumab 200 Milligrams (mg)
Number of Participants With Anti-Guselkumab Antibodies Through Week 481
SecondaryNumber of Participants With Neutralizing-Guselkumab Antibodies Through Week 48

Number of participants with neutralizing-guselkumab antibodies through Week 48 were reported.

Time frame:
From Week 0 through Week 48
Reported as:
Count of participants · Participants
Number of Participants With Neutralizing-Guselkumab Antibodies Through Week 48
ParticipantsGuselkumab 200 Milligrams (mg)
Number of Participants With Neutralizing-Guselkumab Antibodies Through Week 480
SecondaryChange From Baseline in Inflammatory Pharmacodynamic (PD) Marker: C-reactive Protein (CRP) Concentration

Change from baseline in inflammatory PD marker of CRP concentration were reported.

Time frame:
Baseline (Week 0), Weeks 4, 8, 12, 16, 20, 24, 32, 40 and 48
Reported as:
Median · milligrams per liter (mg/L)
Change From Baseline in Inflammatory Pharmacodynamic (PD) Marker: C-reactive Protein (CRP) Concentration
milligrams per liter (mg/L)Guselkumab 200 Milligrams (mg)
Week 4-1.65 (-38.90 to -0.15)
Week 8-2.20 (-36.55 to -0.25)
Week 12-2.40 (-44.20 to -0.20)
Week 16-0.90 (-44.10 to -0.30)
Week 20-0.70 (-45.20 to 0.20)
Week 24-1.60 (-45.10 to -0.20)
Week 32-1.25 (-30.50 to -0.40)
Week 40-1.05 (-31.90 to -0.20)
Week 48-1.65 (-33.40 to -0.10)
SecondaryChange From Baseline in Inflammatory PD Marker: Fecal Calprotectin (FC) Levels

Change from baseline in inflammatory PD marker of FC levels were reported.

Time frame:
Baseline (Week 0), Weeks 4, 8, 12, 24, and 48
Reported as:
Median · milligrams per kilogram (mg/kg)
Change From Baseline in Inflammatory PD Marker: Fecal Calprotectin (FC) Levels
milligrams per kilogram (mg/kg)Guselkumab 200 Milligrams (mg)
Week 4-270.0 (-817.0 to -45.0)
Week 8-252.5 (-1614.5 to -79.0)
Week 12-380.0 (-1563.0 to -110.0)
Week 24-310.0 (-1722.0 to -87.0)
Week 48-280.0 (-1678.0 to -123.0)
SecondaryChange From Baseline in Crohn's Disease Activity Index (CDAI) Score at Week 48 by Serum Guselkumab Concentration Quartiles at Week 48

Change from baseline in CDAI score at Week 48 by serum guselkumab concentration quartiles at Week 48 were reported. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.

Time frame:
At Week 48
Reported as:
Mean · score on a scale
Change From Baseline in Crohn's Disease Activity Index (CDAI) Score at Week 48 by Serum Guselkumab Concentration Quartiles at Week 48
score on a scaleGuselkumab 200 Milligrams (mg)
<= 1st Quartile Concentration-171.7 ± 152.12
> 1st Quartile and <= 2nd Quartile Concentration-137.6 ± 74.78
>2nd Quartile and <= 3rd Quartile Concentration-157.5 ± 124.85
> 3rd Quartile Concentration-146.0 ± 111.21
SecondaryNumber of Participants in Clinical Response at Week 48 by Serum Guselkumab Concentration Quartiles at Week 48

Number of participants in clinical response at Week 48 by serum guselkumab concentration quartiles at Week 48 were reported. Clinical response was defined as a \>=100-point reduction from baseline in CDAI score or CDAI score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.

Time frame:
At Week 48
Reported as:
Count of participants · Participants
Number of Participants in Clinical Response at Week 48 by Serum Guselkumab Concentration Quartiles at Week 48
ParticipantsGuselkumab 200 Milligrams (mg)
<= 1st Quartile Concentration8
> 1st Quartile and <= 2nd Quartile Concentration8
>2nd Quartile and <= 3rd Quartile Concentration7
> 3rd Quartile Concentration8
SecondaryNumber of Participants in Clinical Remission at Week 48 by Serum Guselkumab Concentration Quartiles at Week 48

Number of participants in clinical remission at Week 48 by serum guselkumab concentration quartiles at Week 48 were reported. Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.

Time frame:
At Week 48
Reported as:
Count of participants · Participants
Number of Participants in Clinical Remission at Week 48 by Serum Guselkumab Concentration Quartiles at Week 48
ParticipantsGuselkumab 200 Milligrams (mg)
<= 1st Quartile Concentration7
> 1st Quartile and <= 2nd Quartile Concentration7
>2nd Quartile and <= 3rd Quartile Concentration7
> 3rd Quartile Concentration8
SecondaryNumber of Participants in Endoscopic Response at Week 48 by Serum Guselkumab Concentration Quartiles at Week 48

Number of participants in endoscopic response at Week 48 by serum guselkumab concentration quartiles at Week 48 were reported. Endoscopic response was defined as \>=50 % improvement from baseline in SES-CD score or SES-CD score less than or equal to (\<=) 2. The SES-CD was based on evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. Each endoscopic component was scored from 0 (best) to 3 (worst) for each segment, resulting in a total score of up to 15 for each component, except for narrowing component which only attain a maximum total score of 11 because, presence of a narrowing that cannot be passed can be only observed once. The total SES-CD score was sum of all component scores across all segments and it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.

Time frame:
At Week 48
Reported as:
Count of participants · Participants
Number of Participants in Endoscopic Response at Week 48 by Serum Guselkumab Concentration Quartiles at Week 48
ParticipantsGuselkumab 200 Milligrams (mg)
<= 1st Quartile Concentration4
> 1st Quartile and <= 2nd Quartile Concentration4
>2nd Quartile and <= 3rd Quartile Concentration5
> 3rd Quartile Concentration5
SecondaryNumber of Participants in Endoscopic Remission at Week 48 by Serum Guselkumab Concentration Quartiles at Week 48

Number of participants in endoscopic remission at Week 48 by serum guselkumab concentration quartiles at Week 48 were reported. Endoscopic remission: an SES-CD score \<= 4 with at least a 2-point reduction from baseline and no sub score \>1 in any individual subcomponent. The SES-CD was based on evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. Each endoscopic component was scored from 0 (best) to 3 (worst) for each segment, resulting in total score of 15 for each component, except for narrowing component which only attain a maximum total score of 11 because, presence of a narrowing that cannot be passed can be only observed once. The total SES-CD score was sum of all component scores (all segments) \& it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.

Time frame:
At Week 48
Reported as:
Count of participants · Participants
Number of Participants in Endoscopic Remission at Week 48 by Serum Guselkumab Concentration Quartiles at Week 48
ParticipantsGuselkumab 200 Milligrams (mg)
<= 1st Quartile Concentration2
> 1st Quartile and <= 2nd Quartile Concentration3
>2nd Quartile and <= 3rd Quartile Concentration4
> 3rd Quartile Concentration4
SecondaryChange From Baseline in the Average Daily Prednisone-equivalent (P.Eq) Oral Corticosteroid Dose (Excluding Budesonide) Through Week 48 Among Participants Receiving Oral Corticosteroids Other Than Budesonide at Baseline

Change from baseline in the average daily P.Eq oral corticosteroid dose (excluding Budesonide) through Week 48 among participants receiving oral corticosteroids other than Budesonide at baseline were reported.

Time frame:
Baseline (Week 0), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48
Reported as:
Mean · milligram per day (mg/day)
Change From Baseline in the Average Daily Prednisone-equivalent (P.Eq) Oral Corticosteroid Dose (Excluding Budesonide) Through Week 48 Among Participants Receiving Oral Corticosteroids Other Than Budesonide at Baseline
milligram per day (mg/day)Guselkumab 200 Milligrams (mg)
Week 40.00 ± 0.000
Week 80.00 ± 0.000
Week 120.00 ± 0.000
Week 16-9.06 ± 6.722
Week 20-13.13 ± 8.509
Week 24-13.75 ± 7.500
Week 28-13.75 ± 7.500
Week 32-13.75 ± 7.500
Week 36-13.75 ± 7.500
Week 40-13.75 ± 7.500
Week 44-13.75 ± 7.500
Week 48-13.75 ± 7.500
SecondaryNumber of Participants Not Receiving Concomitant Corticosteroids at Week 48 Among Participants Receiving Concomitant Corticosteroids at Baseline

Number of participants not receiving concomitant corticosteroids at Week 48 among participants receiving concomitant corticosteroids at baseline were reported.

Time frame:
At Week 48
Reported as:
Count of participants · Participants
Number of Participants Not Receiving Concomitant Corticosteroids at Week 48 Among Participants Receiving Concomitant Corticosteroids at Baseline
ParticipantsGuselkumab 200 Milligrams (mg)
Number of Participants Not Receiving Concomitant Corticosteroids at Week 48 Among Participants Receiving Concomitant Corticosteroids at Baseline9
SecondaryNumber of Participants Not Receiving Concomitant Corticosteroids for at Least 30 Days Prior to Week 48 Among Participants Receiving Concomitant Corticosteroids at Baseline

Number of participants not receiving concomitant corticosteroids for at least 30 days prior to Week 48 among participants receiving concomitant corticosteroids at baseline were reported.

Time frame:
Up to Week 48
Reported as:
Count of participants · Participants
Number of Participants Not Receiving Concomitant Corticosteroids for at Least 30 Days Prior to Week 48 Among Participants Receiving Concomitant Corticosteroids at Baseline
ParticipantsGuselkumab 200 Milligrams (mg)
Number of Participants Not Receiving Concomitant Corticosteroids for at Least 30 Days Prior to Week 48 Among Participants Receiving Concomitant Corticosteroids at Baseline9
SecondaryNumber of Participants Not Receiving Concomitant Corticosteroids for at Least 90 Days Prior to Week 48 Among Participants Receiving Concomitant Corticosteroids at Baseline

Number of participants not receiving concomitant corticosteroids for at least 90 days prior to Week 48 among participants receiving concomitant corticosteroids at baseline were reported.

Time frame:
Up to Week 48
Reported as:
Count of participants · Participants
Number of Participants Not Receiving Concomitant Corticosteroids for at Least 90 Days Prior to Week 48 Among Participants Receiving Concomitant Corticosteroids at Baseline
ParticipantsGuselkumab 200 Milligrams (mg)
Number of Participants Not Receiving Concomitant Corticosteroids for at Least 90 Days Prior to Week 48 Among Participants Receiving Concomitant Corticosteroids at Baseline9
SecondaryNumber of Participants With Clinical Response Through LTE Phase

Number of participants with clinical response through LTE phase were reported. Clinical response was defined as a \>=100-point reduction from baseline in CDAI score or CDAI score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.

Time frame:
Weeks 96, 144, 192, and 240
Reported as:
Count of participants · Participants
Number of Participants With Clinical Response Through LTE Phase
ParticipantsGuselkumab 200 Milligrams (mg)
Week 9627
Week 14418
Week 1929
Week 2403
SecondaryNumber of Participants With Clinical-biomarker Response Through LTE Phase

Number of participants with clinical-biomarker response through LTE phase were reported. Clinical-biomarker response was defined as clinical response based on CDAI score and \>=50% reduction from baseline in CRP or FC. Clinical response: a \>=100-point reduction from baseline in CDAI score or CDAI score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug\[s\] and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.

Time frame:
Weeks 96, 144, 192, and 240
Reported as:
Count of participants · Participants
Number of Participants With Clinical-biomarker Response Through LTE Phase
ParticipantsGuselkumab 200 Milligrams (mg)
Week 9624
Week 14418
Week 1929
Week 2403
SecondaryNumber of Participants With Clinical Remission Through LTE Phase

Number of participants with clinical remission through LTE phase were reported. Clinical remission was defined as a CDAI score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.

Time frame:
Weeks 96, 144, 192, and 240
Reported as:
Count of participants · Participants
Number of Participants With Clinical Remission Through LTE Phase
ParticipantsGuselkumab 200 Milligrams (mg)
Week 9627
Week 14416
Week 1928
Week 2403
SecondaryNumber of Participants With Endoscopic Response Through LTE Phase

Number of participants in endoscopic response through LTE phase were reported. Endoscopic response was defined as \>=50 % improvement from baseline in SES-CD score or SES-CD score \<=2. The SES-CD was based on evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. Each endoscopic component was scored from 0 (best) to 3 (worst) for each segment, resulting in a total score of up to 15 for each component, except for narrowing component which only attain a maximum total score of 11 because, presence of a narrowing that cannot be passed can be only observed once. The total SES-CD score was sum of all component scores across all segments and it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.

Time frame:
Weeks 96, 144, 192, and 240
Reported as:
Count of participants · Participants
Number of Participants With Endoscopic Response Through LTE Phase
ParticipantsGuselkumab 200 Milligrams (mg)
Week 9613
Week 1449
Week 1924
Week 2402
SecondaryNumber of Participants With Endoscopic Remission Through LTE Phase

Number of participants in endoscopic remission through LTE phase were reported. Endoscopic remission was defined as an SES-CD score \<= 4 with at least a 2-point reduction from baseline and no sub score \>1 in any individual subcomponent. The SES-CD was based on evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. Each endoscopic component was scored from 0 (best) to 3 (worst) for each segment, resulting in total score of 15 for each component, except for narrowing omponent which only attain a maximum total score of 11 because, presence of a narrowing that cannot be passed can be only observed once. The total SES-CD score was sum of all component scores (all segments) \& it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.

Time frame:
Weeks 96, 144, 192, and 240
Reported as:
Count of participants · Participants
Number of Participants With Endoscopic Remission Through LTE Phase
ParticipantsGuselkumab 200 Milligrams (mg)
Week 9613
Week 1448
Week 1923
Week 2401
SecondaryNumber of Participants With Endoscopic Healing Through LTE Phase

Number of participants With endoscopic healing through LTE phase were reported. Endoscopic healing was defined as the absence of mucosal ulcerations.

Time frame:
Weeks 96, 144, 192, and 240
Reported as:
Count of participants · Participants
Number of Participants With Endoscopic Healing Through LTE Phase
ParticipantsGuselkumab 200 Milligrams (mg)
Week 968
Week 1447
Week 1922
Week 2401
SecondaryChange From Baseline in SES-CD Score During LTE Phase

Change from baseline in SES-CD score during LTE phase were reported. The SES-CD was based on evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. Each endoscopic component was scored from 0 (best) to 3 (worst) for each segment, resulting in a total score of up to 15 for each component, except for narrowing component which only attain a maximum total score of 11 because, presence of a narrowing that cannot be passed can be only observed once. The total SES-CD score was sum of all component scores across all segments and it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.

Time frame:
Baseline (Week 0), 96, 144, 192, and 240
Reported as:
Mean · score on a scale
Change From Baseline in SES-CD Score During LTE Phase
score on a scaleGuselkumab 200 Milligrams (mg)
Week 96-4.9 ± 5.98
Week 144-5.1 ± 5.90
Week 192-5.1 ± 6.66
Week 240-10.7 ± 10.07
SecondaryNumber of Participants With Patient-reported Outcome(s) (PRO)-2 Remission During LTE Phase

Number of participants with PRO-2 remission during LTE phase were reported. PRO-2 remission was defined as abdominal pain (AP) mean daily score at or below 1 and stool frequency (SF) mean daily score at or below 3, and no worsening of AP or SF from baseline. Mean daily AP score was defined as the sum of abdominal pain/cramps ratings in the previous 7 days in a diary card divided by the total number of days assessments were performed. Average daily SF score was defined as the sum of number of liquid or very soft stools in the previous 7 days in a diary card divided by the total number of days assessments were performed. Mean daily SF and AP scores score at a scheduled visit were not calculated if total number of days of assessment was less than 5. Higher PRO-2 scores indicated more severe disease.

Time frame:
Weeks 96, 144, 192, and 240
Reported as:
Count of participants · Participants
Number of Participants With Patient-reported Outcome(s) (PRO)-2 Remission During LTE Phase
ParticipantsGuselkumab 200 Milligrams (mg)
Week 9618
Week 14414
Week 1926
Week 2402
SecondaryNumber of Participants With Any Crohn's Disease-related Hospitalizations and/or Surgeries During the Study

Number of participants with any Crohn's Disease-related hospitalizations and/or surgeries during the study were reported.

Time frame:
From Week 0 up to final efficacy visit for each participant (up to Week 248)
Reported as:
Count of participants · Participants
Number of Participants With Any Crohn's Disease-related Hospitalizations and/or Surgeries During the Study
ParticipantsGuselkumab 200 Milligrams (mg)
Number of Participants With Any Crohn's Disease-related Hospitalizations and/or Surgeries During the Study0
SecondarySerum Guselkumab Concentrations During LTE Phase

Serum guselkumab concentrations during LTE phase were reported.

Time frame:
Predose at Weeks 96, 144, 192, and 240
Reported as:
Mean · mcg/mL
Serum Guselkumab Concentrations During LTE Phase
mcg/mLGuselkumab 200 Milligrams (mg)
Week 96: pre dose9.308 ± 4.7275
Week 144: pre dose8.886 ± 3.7197
Week 192: pre dose8.819 ± 3.5263
Week 240: pre dose6.765 ± 0.9600
SecondaryNumber of Participants With Anti-Guselkumab Antibodies During the Study

Number of participants with anti-guselkumab antibodies during the study were reported.

Time frame:
From Week 0 up to the final immunogenicity visit for each participant (up to Week 248)
Reported as:
Count of participants · Participants
Number of Participants With Anti-Guselkumab Antibodies During the Study
ParticipantsGuselkumab 200 Milligrams (mg)
Number of Participants With Anti-Guselkumab Antibodies During the Study5
SecondaryNumber of Participants With Neutralizing Antibodies to Guselkumab During the Study

Number of participants with neutralizing-guselkumab antibodies during the study were reported.

Time frame:
From Week 0 up to the final immunogenicity visit for each participant (up to Week 248)
Reported as:
Count of participants · Participants
Number of Participants With Neutralizing Antibodies to Guselkumab During the Study
ParticipantsGuselkumab 200 Milligrams (mg)
Number of Participants With Neutralizing Antibodies to Guselkumab During the Study0
SecondaryChange From Baseline in Inflammatory Pharmacodynamic (PD) Marker: C-reactive Protein (CRP) Concentration During LTE Phase

Change from baseline in inflammatory PD marker of CRP concentration during LTE phase were reported.

Time frame:
Baseline (Week 0), Weeks 64, 80, 96, 112, 128, 144, 160, 176, 192, 208, 224, and 240
Reported as:
Median · mg/L
Change From Baseline in Inflammatory Pharmacodynamic (PD) Marker: C-reactive Protein (CRP) Concentration During LTE Phase
mg/LGuselkumab 200 Milligrams (mg)
Week 64-2.45 (-32.45 to -0.10)
Week 80-2.30 (-32.80 to -0.15)
Week 96-1.60 (-45.10 to -0.20)
Week 112-2.30 (-27.60 to -0.10)
Week 128-2.90 (-47.70 to -0.40)
Week 144-2.60 (-44.20 to -0.30)
Week 160-7.40 (-50.70 to -1.25)
Week 176-11.10 (-52.10 to -0.90)
Week 192-14.90 (-52.50 to -0.80)
Week 208-15.00 (-49.10 to -0.75)
Week 224-5.80 (-25.45 to -0.10)
Week 240-11.20 (-41.70 to -0.90)
SecondaryChange From Baseline in Inflammatory PD Marker: FC Levels Concentration During LTE Phase

Change from baseline in inflammatory PD marker of FC levels during LTE phase were reported.

Time frame:
Baseline (Week 0), Weeks 64, 80, 96, 112, 128, 144, 160, 176, 192, 208, 224, and 240
Reported as:
Median · mg/L
Change From Baseline in Inflammatory PD Marker: FC Levels Concentration During LTE Phase
mg/LGuselkumab 200 Milligrams (mg)
Week 64-281.0 (-1690.0 to -114.0)
Week 80-339.5 (-1816.5 to -134.5)
Week 96-337.0 (-1912.0 to -138.0)
Week 112-319.0 (-1819.0 to -138.0)
Week 128-319.0 (-2616.0 to -155.0)
Week 144-270.0 (-2624.0 to -158.0)
Week 160-660.0 (-1885.0 to -203.0)
Week 176-1619.0 (-5306 to -155)
Week 192-1579.5 (-2804.0 to -319.0)
Week 208-1684.0 (-1903.0 to -230.0)
Week 224-1625.0 (-2449.0 to -811.0)
Week 240-1955.0 (-3057.0 to -1322.0)
SecondaryChange From Baseline in CDAI Score at Week 96 by Serum Guselkumab Concentration Quartiles at Week 96

Change from baseline in CDAI score at Week 96 by serum guselkumab concentration quartiles at Week 96 were reported. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.

Time frame:
Baseline (Week 0) and Week 96
Reported as:
Mean · score on a scale
Change From Baseline in CDAI Score at Week 96 by Serum Guselkumab Concentration Quartiles at Week 96
score on a scaleGuselkumab 200 Milligrams (mg)
<=1st Quartile Concentration-155.3 ± 118.52
>1st Quartile and <=2nd Quartile Concentration-140.3 ± 127.35
>2nd Quartile and <=3rd Quartile Concentration-208.5 ± 144.33
>3rd Quartile Concentration-152.0 ± 105.49
SecondaryNumber of Participants in Clinical Response at Week 96 by Serum Guselkumab Concentration Quartiles at Week 96

Number of participants in clinical response at Week 96 by serum guselkumab concentration quartiles at Week 96 were reported. Clinical response was defined as a \>=100-point reduction from baseline in CDAI score or CDAI score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.

Time frame:
At Week 96
Reported as:
Count of participants · Participants
Number of Participants in Clinical Response at Week 96 by Serum Guselkumab Concentration Quartiles at Week 96
ParticipantsGuselkumab 200 Milligrams (mg)
<=1st Quartile Concentration7
>1st Quartile and <=2nd Quartile Concentration5
>2nd Quartile and <=3rd Quartile Concentration8
>3rd Quartile Concentration7
SecondaryNumber of Participants in Clinical Remission at Week 96 by Serum Guselkumab Concentration Quartiles at Week 96

Number of participants in clinical remission at Week 96 by serum guselkumab concentration quartiles at Week 96 were reported. Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) in general: higher score indicated higher disease activities and a decrease in total CDAI score over time indicated improvement in disease activity.

Time frame:
At Week 96
Reported as:
Count of participants · Participants
Number of Participants in Clinical Remission at Week 96 by Serum Guselkumab Concentration Quartiles at Week 96
ParticipantsGuselkumab 200 Milligrams (mg)
<=1st Quartile Concentration7
>1st Quartile and <=2nd Quartile Concentration5
>2nd Quartile and <=3rd Quartile Concentration8
>3rd Quartile Concentration7
SecondaryNumber of Participants in Endoscopic Response at Week 96 by Serum Guselkumab Concentration Quartiles at Week 96

Number of participants in endoscopic response at Week 96 by serum guselkumab concentration quartiles at Week 96 were reported. Endoscopic response was defined as \>=50 % improvement from baseline in SES-CD score or SESCD score less than or equal to (\<=) 2. The SES-CD was based on evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. Each endoscopic component was scored from 0 (best) to 3 (worst) for each segment, resulting in a total score of up to 15 for each component, except for narrowing component which only attain a maximum total score of 11 because, presence of a narrowing that cannot be passed can be only observed once. The total SES-CD score was sum of all component scores across all segments and it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.

Time frame:
At Week 96
Reported as:
Count of participants · Participants
Number of Participants in Endoscopic Response at Week 96 by Serum Guselkumab Concentration Quartiles at Week 96
ParticipantsGuselkumab 200 Milligrams (mg)
<=1st Quartile Concentration4
>1st Quartile and <=2nd Quartile Concentration4
>2nd Quartile and <=3rd Quartile Concentration3
>3rd Quartile Concentration2
SecondaryNumber of Participants in Endoscopic Remission at Week 96 by Serum Guselkumab Concentration Quartiles at Week 96

Number of participants in endoscopic remission at Week 96 by serum guselkumab concentration quartiles at Week 96 were reported. Endoscopic remission: an SES-CD score \<= 4 with at least a 2-point reduction from baseline and no sub score \>1 in any individual subcomponent. The SES-CD was based on evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. Each endoscopic component was scored from 0 (best) to 3 (worst) for each segment, resulting in total score of 15 for each component, except for narrowing component which only attain a maximum total score of 11 because, presence of a narrowing that cannot be passed can be only observed once. The total SES-CD score was sum of all component scores (all segments) \& it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.

Time frame:
At Week 96
Reported as:
Count of participants · Participants
Number of Participants in Endoscopic Remission at Week 96 by Serum Guselkumab Concentration Quartiles at Week 96
ParticipantsGuselkumab 200 Milligrams (mg)
>1st Quartile Concentration4
>1st Quartile and <=2nd Quartile Concentration4
>2nd Quartile and <=3rd Quartile Concentration3
>3rd Quartile Concentration2
SecondaryChange From Baseline in the Average Daily Prednisone-equivalent (P.Eq) Oral Corticosteroid Dose (Excluding Budesonide) During LTE Phase Among Participants Receiving Oral Corticosteroids Other Than Budesonide at Baseline

Change from baseline in the average daily P.Eq oral corticosteroid dose (excluding Budesonide) during LTE phase among participants receiving oral corticosteroids other than Budesonide at baseline were reported.

Time frame:
Baseline (Week 0), Weeks 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, 112, 116, 120, 124, 128, 132, 136, 140, 144, 148, 152, 156, 160, 164, 168, 172, 176, 180, 184, 188, 192, 196, 200, 204, 208, 212, 216, 220, 224, 228, and 232
Reported as:
Mean · mg/day
Change From Baseline in the Average Daily Prednisone-equivalent (P.Eq) Oral Corticosteroid Dose (Excluding Budesonide) During LTE Phase Among Participants Receiving Oral Corticosteroids Other Than Budesonide at Baseline
mg/dayGuselkumab 200 Milligrams (mg)
Week 52-13.75 ± 7.500
Week 56-13.75 ± 7.500
Week 60-15.00 ± 8.660
Week 64-13.75 ± 7.500
Week 68-15.00 ± 8.660
Week 72-13.75 ± 7.500
Week 76-15.00 ± 8.660
Week 80-13.75 ± 7.500
Week 84-15.00 ± 8.660
Week 88-13.75 ± 7.500
Week 92-13.75 ± 7.500
Week 96-13.75 ± 7.500
Week 100-13.75 ± 7.500
Week 104-13.75 ± 7.500
Week 108-13.75 ± 7.500
Week 112-13.75 ± 7.500
Week 116-13.75 ± 7.500
Week 120-13.75 ± 7.500
Week 124-13.75 ± 7.500
Week 128-13.75 ± 7.500
Week 132-13.75 ± 7.500
Week 136-13.75 ± 7.500
Week 140-13.75 ± 7.500
Week 144-13.75 ± 7.500
Week 148-13.75 ± 7.500
Week 152-13.75 ± 7.500
Week 156-13.75 ± 7.500
Week 160-13.75 ± 7.500
Week 164-13.75 ± 7.500
Week 168-13.75 ± 7.500
Week 172-11.67 ± 7.638
Week 176-11.67 ± 7.638
Week 180-11.67 ± 7.638
Week 184-11.67 ± 7.638
Week 188-11.67 ± 7.638
Week 192-11.67 ± 7.638
Week 196-11.67 ± 7.638
Week 200-11.67 ± 7.638
Week 204-11.67 ± 7.638
Week 208-11.67 ± 7.638
Week 212-15.00 ± 7.071
Week 216-11.67 ± 7.638
Week 220-15.00 ± 7.071
Week 224-20.00 ± NA
Week 228-20.00 ± NA
Week 232-20.00 ± NA

Adverse events

Collected over All cause mortality (Open-label phase [OL phase]): From screening (Week -8) up to Week 48; All cause mortality (LTE phase): From Week 48 up to Week 248. SAEs and Other AEs: From baseline (Week 0) up to Week 48; SAEs and Other AEs (LTE phase): From Week 48 up to Week 248. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open Label Phase: Guselkumab 200 mg0/38 (0%)3/38 (7.9%)30/38 (78.9%)
LTE Phase: Guselkumab 200 mg0/32 (0%)10/32 (31.3%)32/32 (100%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventOpen Label Phase: Guselkumab 200 mgLTE Phase: Guselkumab 200 mg
VertigoEar and labyrinth disorders0/381/32
Anogenital DysplasiaGastrointestinal disorders0/381/32
Crohn's DiseaseGastrointestinal disorders0/381/32
Ileal StenosisGastrointestinal disorders0/381/32
Intestinal Mucosal TearGastrointestinal disorders0/381/32
Small Intestinal ObstructionGastrointestinal disorders0/381/32
Small Intestinal StenosisGastrointestinal disorders0/381/32
Colorectal AdenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/381/32
MyelopathyNervous system disorders0/381/32
UreterolithiasisRenal and urinary disorders0/381/32
Most frequent other events
Showing 10 of 92
Most frequent other events
EventOpen Label Phase: Guselkumab 200 mgLTE Phase: Guselkumab 200 mg
NasopharyngitisInfections and infestations4/3817/32
PyrexiaGeneral disorders15/386/32
Covid-19Infections and infestations1/388/32
Back PainMusculoskeletal and connective tissue disorders2/386/32
HeadacheNervous system disorders6/385/32
Coronavirus InfectionInfections and infestations0/383/32
InfluenzaInfections and infestations0/383/32
Rhinitis AllergicRespiratory, thoracic and mediastinal disorders2/383/32
DiarrhoeaGastrointestinal disorders1/382/32
ProctitisGastrointestinal disorders0/382/32

Baseline characteristics

Age, Continuous
Age, Continuous(years)Guselkumab 200 Milligrams (mg)
Mean42.0 ± 14.58
Sex: Female, Male
Sex: Female, Male(Participants)Guselkumab 200 Milligrams (mg)
Female14
Male24
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Guselkumab 200 Milligrams (mg)
Hispanic or Latino0
Not Hispanic or Latino38
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Guselkumab 200 Milligrams (mg)
American Indian or Alaska Native0
Asian38
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Guselkumab 200 Milligrams (mg)
Japan38
08

Study locations

25 sites
  • KOKIKAI Tokatsu Tsujinaka Hospital
    Abiko, 270-1168, Japan
  • Institute of Science Tokyo Hospital
    Bunkyō City, 113 8519, Japan
  • Hitachi General Hospital
    Hitachi, 317-0077, Japan
  • Asahikawa Medical University Hospital
    Hokkaido, 078 8510, Japan
  • Ofuna Chuo Hospital
    Kamakura, 247-0056, Japan
  • Kishiwada Tokushukai Hospital
    Kishiwada, 5960042, Japan
  • Kumamoto University Hospital
    Kumamoto, 860-8556, Japan
  • Japanese Red Cross Kumamoto Hospital
    Kumamoto, 861-8520, Japan
  • Kyorin University Hospital
    Mitaka, 181-8611, Japan
  • Kenseikai Dongo Hospital
    Nara, 635-0022, Japan
  • Hyogo Medical University Hospital
    Nishinomiya Shi, 663 8501, Japan
  • Okayama University Hospital
    Okayama, 700-8558, Japan
  • Ishida Clinic of IBD and Gastroenterology
    Ōita, 870 0823, Japan
  • Saga University Hospital
    Saga, 849-8501, Japan
  • Kitasato University Hospital
    Sagamihara, 252-0375, Japan
  • Saitama Medical Center
    Saitama, 350 8550, Japan
  • Sapporo Tokushukai Hospital
    Sapporo, 004-0041, Japan
  • Sendai Kosei Hospital
    Sendai Miyagi, 9810914, Japan
  • Jichi Medical University Hospital
    Shimotsuke, 329-0498, Japan
  • National Center for Global Health and Medicine
    Shinjuku- Ku, 162-8655, Japan
  • Tokyo Women's Medical University Hospital
    Shinjuku-ku, 162-8666, Japan
  • Tokyo Metropolitan Bokutoh Hospital
    Sumida Ku, 130 8575, Japan
  • Osaka Medical and Pharmaceutical University Hospital
    Takatsuki, 569-8686, Japan
  • Toyama Prefectural Central Hospital
    Toyama, 9308550, Japan
  • National Hospital Organization Toyohashi Medical Center
    Toyohashi, 441-8570, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Feb 2024, 44 months.

Results were first posted in May 2025, 1 year 2 months after primary completion.

Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 44 months is close to that.

Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2020
First posted
May 21, 2020
StartActual
Jun 10, 2020
Primary completionActual
Feb 29, 2024
CompletionActual
Sep 12, 2025
Results first posted
May 20, 2025
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Oct 7, 2026
Documents
Secondary outcomes
20 added, 1 description edited
What changed in the outcomes
  • AddedNumber of Participants With Clinical Response Through LTE PhaseTime frame: Weeks 96, 144, 192, and 240
  • AddedNumber of Participants With Clinical-biomarker Response Through LTE PhaseTime frame: Weeks 96, 144, 192, and 240
  • AddedNumber of Participants With Clinical Remission Through LTE PhaseTime frame: Weeks 96, 144, 192, and 240
  • AddedNumber of Participants With Endoscopic Response Through LTE PhaseTime frame: Weeks 96, 144, 192, and 240
  • AddedNumber of Participants With Endoscopic Remission Through LTE PhaseTime frame: Weeks 96, 144, 192, and 240
  • AddedNumber of Participants With Endoscopic Healing Through LTE PhaseTime frame: Weeks 96, 144, 192, and 240
  • AddedChange From Baseline in SES-CD Score During LTE PhaseTime frame: Baseline (Week 0), 96, 144, 192, and 240
  • AddedNumber of Participants With Patient-reported Outcome(s) (PRO)-2 Remission During LTE PhaseTime frame: Weeks 96, 144, 192, and 240
  • AddedNumber of Participants With Any Crohn's Disease-related Hospitalizations and/or Surgeries During the StudyTime frame: From Week 0 up to final efficacy visit for each participant (up to Week 248)
  • AddedSerum Guselkumab Concentrations During LTE PhaseTime frame: Predose at Weeks 96, 144, 192, and 240
  • AddedNumber of Participants With Anti-Guselkumab Antibodies During the StudyTime frame: From Week 0 up to the final immunogenicity visit for each participant (up to Week 248)
  • AddedNumber of Participants With Neutralizing Antibodies to Guselkumab During the StudyTime frame: From Week 0 up to the final immunogenicity visit for each participant (up to Week 248)
  • AddedChange From Baseline in Inflammatory Pharmacodynamic (PD) Marker: C-reactive Protein (CRP) Concentration During LTE PhaseTime frame: Baseline (Week 0), Weeks 64, 80, 96, 112, 128, 144, 160, 176, 192, 208, 224, and 240
  • AddedChange From Baseline in Inflammatory PD Marker: FC Levels Concentration During LTE PhaseTime frame: Baseline (Week 0), Weeks 64, 80, 96, 112, 128, 144, 160, 176, 192, 208, 224, and 240
  • AddedChange From Baseline in CDAI Score at Week 96 by Serum Guselkumab Concentration Quartiles at Week 96Time frame: Baseline (Week 0) and Week 96
  • AddedNumber of Participants in Clinical Response at Week 96 by Serum Guselkumab Concentration Quartiles at Week 96Time frame: At Week 96
  • AddedNumber of Participants in Clinical Remission at Week 96 by Serum Guselkumab Concentration Quartiles at Week 96Time frame: At Week 96
  • AddedNumber of Participants in Endoscopic Response at Week 96 by Serum Guselkumab Concentration Quartiles at Week 96Time frame: At Week 96
  • AddedNumber of Participants in Endoscopic Remission at Week 96 by Serum Guselkumab Concentration Quartiles at Week 96Time frame: At Week 96
  • AddedChange From Baseline in the Average Daily Prednisone-equivalent (P.Eq) Oral Corticosteroid Dose (Excluding Budesonide) During LTE Phase Among Participants Receiving Oral Corticosteroids Other Than Budesonide at BaselineTime frame: Baseline (Week 0), Weeks 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, 112, 116, 120, 124, 128, 132, 136, 140, 144, 148, 152, 156, 160, 164, 168, 172, 176, 180, 184, 188, 192, 196, 200, 204, 208, 212, 216, 220, 224, 228, and 232
  • DescriptionNumber of Participants With Clinical Response Through Week 48: how it is measured was reworded
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Posted results revised
    Secondary outcomes 20 added, 1 description edited
    What changed in the outcomes
    • AddedNumber of Participants With Clinical Response Through LTE PhaseTime frame: Weeks 96, 144, 192, and 240
    • AddedNumber of Participants With Clinical-biomarker Response Through LTE PhaseTime frame: Weeks 96, 144, 192, and 240
    • AddedNumber of Participants With Clinical Remission Through LTE PhaseTime frame: Weeks 96, 144, 192, and 240
    • AddedNumber of Participants With Endoscopic Response Through LTE PhaseTime frame: Weeks 96, 144, 192, and 240
    • AddedNumber of Participants With Endoscopic Remission Through LTE PhaseTime frame: Weeks 96, 144, 192, and 240
    • AddedNumber of Participants With Endoscopic Healing Through LTE PhaseTime frame: Weeks 96, 144, 192, and 240
    • AddedChange From Baseline in SES-CD Score During LTE PhaseTime frame: Baseline (Week 0), 96, 144, 192, and 240
    • AddedNumber of Participants With Patient-reported Outcome(s) (PRO)-2 Remission During LTE PhaseTime frame: Weeks 96, 144, 192, and 240
    • AddedNumber of Participants With Any Crohn's Disease-related Hospitalizations and/or Surgeries During the StudyTime frame: From Week 0 up to final efficacy visit for each participant (up to Week 248)
    • AddedSerum Guselkumab Concentrations During LTE PhaseTime frame: Predose at Weeks 96, 144, 192, and 240
    • AddedNumber of Participants With Anti-Guselkumab Antibodies During the StudyTime frame: From Week 0 up to the final immunogenicity visit for each participant (up to Week 248)
    • AddedNumber of Participants With Neutralizing Antibodies to Guselkumab During the StudyTime frame: From Week 0 up to the final immunogenicity visit for each participant (up to Week 248)
    • AddedChange From Baseline in Inflammatory Pharmacodynamic (PD) Marker: C-reactive Protein (CRP) Concentration During LTE PhaseTime frame: Baseline (Week 0), Weeks 64, 80, 96, 112, 128, 144, 160, 176, 192, 208, 224, and 240
    • AddedChange From Baseline in Inflammatory PD Marker: FC Levels Concentration During LTE PhaseTime frame: Baseline (Week 0), Weeks 64, 80, 96, 112, 128, 144, 160, 176, 192, 208, 224, and 240
    • AddedChange From Baseline in CDAI Score at Week 96 by Serum Guselkumab Concentration Quartiles at Week 96Time frame: Baseline (Week 0) and Week 96
    • AddedNumber of Participants in Clinical Response at Week 96 by Serum Guselkumab Concentration Quartiles at Week 96Time frame: At Week 96
    • AddedNumber of Participants in Clinical Remission at Week 96 by Serum Guselkumab Concentration Quartiles at Week 96Time frame: At Week 96
    • AddedNumber of Participants in Endoscopic Response at Week 96 by Serum Guselkumab Concentration Quartiles at Week 96Time frame: At Week 96
    • AddedNumber of Participants in Endoscopic Remission at Week 96 by Serum Guselkumab Concentration Quartiles at Week 96Time frame: At Week 96
    • AddedChange From Baseline in the Average Daily Prednisone-equivalent (P.Eq) Oral Corticosteroid Dose (Excluding Budesonide) During LTE Phase Among Participants Receiving Oral Corticosteroids Other Than Budesonide at BaselineTime frame: Baseline (Week 0), Weeks 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, 112, 116, 120, 124, 128, 132, 136, 140, 144, 148, 152, 156, 160, 164, 168, 172, 176, 180, 184, 188, 192, 196, 200, 204, 208, 212, 216, 220, 224, 228, and 232
    • DescriptionNumber of Participants With Clinical Response Through Week 48: how it is measured was reworded
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04397263
Responsible party
Sponsor
First posted
May 21, 2020
Start date
Jun 10, 2020
Primary completion
Feb 29, 2024
Completion
Sep 12, 2025
Results posted
May 20, 2025
Last update
Oct 7, 2026

Study contacts

Janssen Pharmaceutical K.K., Japan Clinical Trial
study director · Janssen Pharmaceutical K.K.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guselkumab

Start the discussion